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CHAPTER 1 INTRODUCTION 
1.1. Background 
Cancer is accountable for millions of deaths annually worldwide. According 
to the American Cancer Society, cancer is the second most common cause of 
death in the United States. Approximately 1.7 million new cancer cases are 
expected and about 600,000 Americans are expected to die of cancer in 2016 [1]. 
Chemotherapy, radiotherapy, and photothermal therapy are the most common 
treatments for cancer. Chemotherapy is the most common strategy in cancer 
treatment because of its higher efficacy as compared to other types of treatments 
[2–5]. In most cases, cancer diagnosis in the early stage is difficult. Most of the 
patients are diagnosed at the late stage of cancer with a poor prognosis. In the 
advanced stage of cancer, chemotherapy and radiotherapy are the only options. 
However, the development of chemotherapeutic drug resistance is the most 
common reason leading to the failure of cancer treatment. The conventional 
treatment with the systemic distribution of chemotherapeutics is problematic and 
shows a significant flow that can make the difference between success and failure 
[6]. High doses are often required to accumulate adequate amounts of 
chemotherapeutic agents at the tumor site to achieve desirable therapeutic 
efficacy. However, larger doses possess a higher risk of adverse side-effects with 
the increase of toxicity in non-targeted sites or normal tissues. The bleak prognosis 
for patients diagnosed with metastatic cancer along with the low therapeutic 
efficacy and the recurrence of cancer in conventional chemotherapy are prompting 
clinical medicine to adopt a new strategy to detect cancer in early stage and to 
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deliver the anticancer drugs specifically to tumor site to enhance therapeutic 
efficiency and minimize side effects. 
1.2. CDF (3,4-difluorobenzylidene diferuloylmethane) – a highly 
potent but extremely lipophilic anticancer drug 
In our earlier studies  3,4-difluorobenzylidene diferuloylmethane (CDF), a 
synthetic analog of a potent flavonoid anticancer compound has shown 16-fold 
increased half-life and high anticancer activity compared to its natural analog, 
diferuloylmethane when tested on pancreatic cancer cells [7–9]. The observed 
improvement in properties of CDF was attributed to its much higher stability and 
bioavailability compared to the natural counterpart. CDF could inhibit the growth of 
cancer cells through down-regulation of multiple miRNAs, up-regulation of 
phosphatase and tensin homolog (PTEN), and attenuation of histone 
methyltransferase EZH2 [10–12]. These findings strongly indicate that CDF could 
be a good candidate for several cancers, including cervical cancer. However, one 
significant problem limiting CDF from further preclinical and clinical testing is its 
very poor aqueous solubility. In our previous studies, we successfully overcame 
CDF’s solubility problem by using dendrimer and micellar nanocarriers [7,13]. In 
those studies, CDF has shown a significant anticancer activity on tested cancer 
cells including triple marker positive stem-like pancreatic cancer cells. 
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1.3. Polyamidoamine (PAMAM) dendrimers in targeted drug 
delivery 
1.3.1. What are PAMAM dendrimers? 
PAMAM dendrimers are a relatively novel class of polymers with a well-
defined, nano-sized, highly branched and monodispersed structures with 
numerous hydrophilic reactive amine groups on the periphery and lipophilic 
internal cavities. PAMAM dendrimers are known for their ability to encapsulate 
hydrophobic drugs in their internal cavities to enhance the aqueous solubility of 
these hydrophobic compounds [14–16]. The larger numbers of reactive amine 
groups on the periphery makes PAMAM dendrimers suitable for many biomedical 
applications such as drug conjugation, siRNA and gene complexation, and 
conjugation to bio-recognition molecules to achieve active targeting ability [17,18]. 
When PAMAM dendrimers are used as drug carriers, they can enhance the drug 
biodistribution in tumor site possibly by taking the advantage of enhanced 
permeation and retention effect [19–21]. In addition, it is demonstrated that by 
carrying targeting ligands on the surface, PAMAM dendrimers can achieve active 
receptor targeting. In this regards, one of the most commonly used targeting 
ligands is folic acid (FA). Many types of cancer cells (such as ovarian, colon, lung, 
breast and cervical cancer cells) are known to have a high expression of folate 
receptors on their membranes [22–25]. Drug carriers decorated with FA can 
achieve targeting ability and high accumulation in cancer cells by taking advantage 
of the specific binding of FA with folate receptors overexpressed on these targeted 
cancer cells. Cellular internalization is facilitated via folate-receptor mediated 
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endocytosis and followed by the release of anticancer drug; thus, resulting in a 
better accumulation with minimized toxicity to normal cells. 
1.3.2. Dendrimer mediated tumor targeted delivery: Passive and active 
targeting  
1.3.2.1. Dendrimer-mediated passive targeting strategy 
The passive targeting pathway of dendrimers utilizes the inherent ability of 
macromolecules to extravasate and accumulate specifically in the tumor 
microenvironment based on a phenomenon called the enhanced permeability and 
retention (EPR) effect, which was discovered by Matsumura and Maeda [19]. The 
EPR phenomenon suggested that the rapid proliferation of tumor cells create 
complex networks of blood vessels that are highly disorganized and leaky. The 
dilation of blood vessels is facilitated by excessive levels of vascular permeability 
mediators secreted by tumor cells [4,26–28]. The anatomical and 
pathophysiological abnormalities in tumor environment result in an extensive 
leakage of macromolecules and nanoparticles including dendrimers into the tumor 
interstitium [26,28–30]. In addition, the lymphatic clearance in solid tumors is 
dysfunctional in general. As a consequence, drugs conjugated or encapsulated in 
macromolecules and nanoparticles can attain very high local concentrations in the 
tumor environment with negligible accumulation in the non-targeted or healthy 
organs. Particle size is an important factor dictating the localization and retention 
in tumor tissues. It is observed that nanoparticles in the range of ten to a few 
hundred nanometers can exploit the EPR phenomenon to accumulate in tumor 
tissues [31]. In this regards, dendrimers with a typical size range from 10 to 20 nm 
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are favorable to achieve passive tumor targeting [32]. In addition, dendrimers have 
prolonged half-life in the systemic circulation and can avoid renal excretion due to 
the ability to bind to plasma proteins and biomolecules [33]. As a result, dendrimers 
can retain in the blood for an extended duration and accumulate in the tumor 
environment by EPR effect, suggesting a sustained and controlled delivery profile. 
1.3.2.2. Dendrimer-mediated active targeting strategy 
The passive tumor targeting has numerous challenges due to the 
complexity of the anatomic and pathophysiological barriers in the in vivo biological 
environment. The passive targeting strategy is only effective in highly permeable 
solid tumors. In most cases, the permeability in tumors is relatively poor and non-
uniform; thus, it is difficult to take advantage of EPR effect in these heterogeneous 
and impermeable tumors [34]. These limitations can be resolved to some extent 
by utilizing the active targeting strategy, a phenomenon where specific targeting 
ligands are introduced to the nanostructure to facilitate the selective binding to 
unique and overexpressed receptors on specific tumor cells. In this regards, 
dendrimers with numerous reactive functional groups on the periphery are 
favorable for the conjugation with targeting ligands for the active targeting effect. 
Folic acid is one of the most common targeting ligands for several reasons. 
Folic acid is a low molecular weight B-vitamin whose receptors are found to be 
overexpressed in numerous types of cancer cells, including lung, breast, colon, 
choroid plexus brain, choriocarcinoma, cervical, and ovarian cancers [22,24,35]. 
Folate receptors are known to occur in clusters, giving the ability to enhance 
targeting efficacy by using multiple folic acid moieties on nanoparticles. Many types 
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of cancer cells are known to have a high level expression of folate receptors. 
Healthy cells also express folate receptors but with a significantly lower degree. 
Moreover, folate receptors in healthy cells are in a different location which is not 
accessible from the bloodstream, suggesting that folate receptors in cancer cells 
could be a perfect target for actively targeted drug delivery [22]. 
Because of the small size, folic acid is known to be a stable molecule that 
does not induce an immune response. As compared to an antibody, folic acid is a 
better targeting ligand since its  binding affinity to folate receptors is not diminished 
after its conjugation to macromolecules or nanoparticles [36,37]. In addition, 
antigen expression may change over time; whereas, folate receptors are stable 
because folic acid is a crucial ingredient in biosynthesis needed for cellular 
proliferation [37–39]. After the binding of the folate-decorated nanoparticles, 
endocytosis will occur resulting in the internalization of the folate-decorated 
nanoparticles. Then, folate receptors are recycled to the cell surface and ready for 
binding with the next nanoparticles [40].  
1.4. Biomedical application of Magnetic Resonance Imaging 
1.4.1. Magnetic resonance imaging (MRI)  
MRI is one of the most common clinical diagnostic tools due to its 
noninvasive, tomographic properties that offers superb spatial resolution without 
the dangers of ionizing radiation. Hydrogen nuclei or protons in water molecules 
are the main contributors to MRI signal in biological applications. In a simplistic 
sense, MR imaging is just the proton nuclear magnetic resonance (NMR) in the 
biological systems which yields the intensity maps of the proton relaxation time in 
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tissue [41]. The difference in the proton density and the relaxation time constants 
in the tissue samples gives the contrast in the resulting MR images. However, the 
sensitivity of the MR images is relatively low if we only rely upon these inherent 
contrast mechanisms [42]. This limitation can be addressed by using exogenous 
magnetic agents or contrast agents which can influence the spin relaxation time of 
the local protons thereby enhancing the contrast in the resulting MR images [43–
46]. 
1.4.2. MRI contrast agents  
Among several types of contrast agents, the two major classes are chelated 
paramagnetic ions such as Gadolinium (Gd), and superparamagnetic iron oxide 
nanoparticles (SPIONs). SPIONs have several advantages as compared to 
chelated paramagnetic ions. SPIONs are detectable at nM concentrations or lower, 
whereas chelated paramagnetic ions detection concentration is at the mM in order 
to generate adequate contrast [47]. In addition, paramagnetic chelates need the 
exchange of water protons in order to produce local contrast effects; whereas, 
SPIONs can impact a larger region of tissue without the direct contact with water 
protons by producing magnetic field gradients [39,45,48].  
In recent years, magnetic nanoparticles are getting more attention due to 
their applications in biology and medicine such as enzyme and protein 
immobilization, magnetic resonance imaging, tissue engineering, magnetic cell 
tracking and separation, hyperthermia, and targeted drug and gene delivery 
[49,50]. Drug delivery systems based on magnetic nanoparticle carriers possess 
the ability of magnetic resonance imaging contrast agents as well as the advanced 
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properties of nanocarriers such as the enhanced aqueous solubility, increased 
systemic circulation time, targeting delivery of chemotherapeutic drugs with 
reduced toxicity in normal tissues. Magnetic iron oxide (Fe3O4) nanoparticles, 
especially superparamagnetic iron oxide nanoparticles, have been widely studied 
and shown great potentials in biotechnology because of their biocompatible, inert, 
and excellent superparamagnetism properties [51,52]. In in vivo applications, the 
surface of these magnetic nanoparticles can be modified with polymeric shells 
such as dextran, PEG, chitosan, and dendrimers [53–55]. These polymeric shells 
provide not only the biocompatibility for the magnetic nanoparticles, but also the 
ability for conjugation with biomolecules such as proteins, nucleic acids, enzymes, 
targeting ligands, and drugs [56–59]. 
1.4.3. Iron oxide nanoparticles – Safe and highly effective MRI contrast 
agents 
There are many factors that make iron oxide Fe3O4 excellent MRI contrast 
agents. Iron oxide particles occur naturally in many animals and are currently the 
only inorganic contrast particles approved for in vivo human applications 
(Endorem® or Feridex I.V.®; Advanced Magnetics, Cambridge, Massachusetts, 
USA) [39,60,61]. Iron oxide particles are biodegradable without either acute or 
chronic toxicity [62–65]. Uncoated magnetic iron oxide particles have an LD50 of 
300 to 600 mg iron per kg body weight, and the surface coating has shown to be 
able to improve the biocompatibility of the iron oxides by an order of magnitude 
[39,66]. The typical clinical dose for SPIONs is 1 mg Fe per kg body weight which 
is significantly lower than LD50. It is also a small fraction of the approximately 3500 
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mg of total iron in various forms naturally found in the human body. In addition, 
many studies have shown that the human body has established methods to 
metabolize the excess amount of iron introduced by the particles [48,64,67,68]. 
SPIONs have been studied with many different agents for actively targeted 
MRI. In a study by Cheon et al., SPIONs were modified with dimercaptosuccinic 
acid, followed by the conjugation of Herceptin molecules via the free thiol functional 
groups on the particles. The targeting ability of the particles was demonstrated in 
vitro with different cell lines with a different level of her2/neu expression. The 
results showed a decrease in MRI signal intensity with the increase of the 
expression of her2/neu. In in vivo studies using mice bearing a NIH3T6.7 
xenograft, SPIONs conjugated Herceptin showed an enhanced contrast in MR 
signal as compared to SPIONs conjugated with the irrelevant antibodies [69]. 
Besides antibody, transferrin has been used as a targeting ligand for SPIONs 
[38,70]. Many studies have suggested that SPIONs decorated transferrin could 
benefit from the transferrin receptor-mediated endocytosis, resulting in a higher 
degree of cellular internalization.   
Shi’s group used folic acid as a targeting moiety for SPIONs for targeted 
MRI of tumors. SPIONs were synthesized by co-precipitation method. A layer-by-
layer self-assembly method was used to functionalize SPIONs with dendrimer 
decorated folic acid. The results showed an enhanced in cellular uptake of the 
SPIONs containing folic acid in tumor cells overexpressed folate receptors. MR 
images showed a higher increase in the contrast when incubating the folate-
decorated SPIONs with human epithelial carcinoma cell line (KB cells) indicating 
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the targeting effect of the conjugates [71]. In a recent study done by Akal et al., 
SPIONs were functionalized with APTES ((3-Aminopropyl) triethoxysilane), 
polyethylene glycol (PEG) and folic acid for the targeted delivery of Quercetin for 
brain cancer. Prussian blue staining and fluorescence spectroscopy studies 
showed a higher cellular uptake of the SPIONs containing folic acid. The Quercetin 
loaded folate-decorated SPIONs showed a higher anticancer activity when tested 
on U87 cell line (brain adenocarcinoma cells, which have high expression of folate 
receptors), as compared to L929 cell line (fibroblast cells, which are folic acid 
receptors negative cells). The results are in accordance with previous studies, 
suggesting SPIONs modified with appropriate targeting ligands could result in a 
better accumulation in tumor cells which possess complementary receptor binding 
domains. 
1.5. SPIONs coated FA-PAMAM as a multifunctional agent for 
cancer imaging and therapy 
In this study, SPIONs were synthesized by coprecipitation method, followed 
by surface coating and fabrication of PAMAM-decorated FA. The magnetic 
nanocarriers were used to encapsulate a poorly aqueous soluble but highly potent 
anticancer drug 3,4-difluorobenzylidene diferuloylmethane (CDF), a synthetic 
analog of a potent flavonoid anticancer compound diferuloylmethane. In our 
previous studies, CDF has shown a high anticancer activity when tested on 
pancreatic, cervical, ovarian and lung cancer cells [7–9,72]. The improvement in 
anticancer properties of CDF was attributed to a 16-fold increased half-life, a 
higher stability, and bioavailability as compared to its natural counterpart. CDF has 
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shown to be able to inhibit the growth of cancer cells through down-regulation of 
multiple miRNAs, up-regulation of phosphatase and tensin homolog (PTEN), and 
attenuation of histone methyltransferase EZH2 [10–12]. The theranostic capability 
for cancer imaging and therapy of the magnetic nanocarriers encapsulated CDF 
was examined by in vitro biological studies, cellular uptake, and T2 relaxation 
studies. The results demonstrated that the synthesized magnetic nanocarriers 
could be promising carriers in active targeting cancer imaging and therapy (Fig. 1).
 
Figure 1. The pictorial representation of accumulation of targeted formulation 
(SPIONs@FA-PAMAM-CDF) at the tumor site by EPR-effect, followed by folate 
receptor mediated endocytosis of the formulation due to the specific binding of FA 
to folate receptors overexpressed on cancer cells. 
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CHAPTER 2 EXPERIMENTAL DESIGN 
2.1. Materials 
2.1.1. Reagents 
CDF was synthesized as described earlier [7,13]. Fourth generation (4.0G) 
PAMAM dendrimer, ferrous chloride (FeCl2.4H2O), ferric chloride (FeCl3.6H2O), N-
(3-(dimethylamino) propyl)-N-ethylcarbodiimide hydrochloride (EDC), and 3-[4,5 
dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide (MTT) was purchased from 
Sigma-Aldrich (St. Louis, MO). FA was purchased from Fisher Scientific. Guava 
Nexin Reagent for cell apoptosis kit was purchased from EMD Millipore. All other 
chemicals were of reagent grade and used without any modification. 
2.1.2. Cell lines 
Human cervical cancer cells (HeLa cells) and human ovarian carcinoma 
cells (SKOV3 cells) were used in this study due to their high expression of folate 
receptors [73–76]. HeLa cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM; Fisher Scientific, Waltham MA) with 10% fetal bovine serum 
(FBS) and streptomycin sulfate (10mg/L). SKOV3 cells were cultured in Roswell 
Park Memorial Institute (RPMI) 1640 Medium (Thermo Fisher Scientific, USA) with 
10% FBS and streptomycin sulfate (10mg/L). All cell lines were incubated at 37oC 
in a 5% CO2 air humidified atmosphere. 
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2.2. Superparamagnetic iron oxide nanoparticles (SPIONs) 
synthesis 
Superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized 
using co-precipitation method [77]. Prior to the synthesis, 0.5 M NaOH solution in 
deionized water (DIW) was prepared in a three-neck 500 ml round bottom flask 
(RBF) and degassed by bubbling N2 while stirring at room temperature RT) for 30 
min, followed by degas under vacuum while stirring at RT for another 30 min, then 
was heated to 40oC. Then, ferric chloride FeCl3.H2O (6.56 g, 0.024 mol) and 
ferrous chloride FeCl2.4H2O (2.48 g, 0.012 mol) were dissolved in 25 ml of 
degassed 0.4 M HCl solution in DIW and then added to the RBF through a septum. 
The RBF was heated at 80oC under strong stirring for 1 h. SPIONs were 
precipitated using a strong neodymium N52 magnet and then decant the reaction 
mixture. The SPIONs were washed 5 times by dispersing them back in EtOH (300 
ml) with probe sonication for 10 min, followed by magnet precipitation and decant 
the liquid. A dry powder of SPIONs was obtained by drying under vacuum on a 
rotary evaporator. The product was characterized by Fourier Transform Infrared 
Spectroscopy (FTIR). Hydrodynamic size and zeta potential were characterized by 
dynamic light scattering using Beckman Coulter Delsa Nano. 
2.3. FA-PAMAM decorated SPIONs fabrication 
FA was conjugated to 4th generation PAMAM dendrimers through 
carbodiimide coupling chemistry according to our previously reported method [72]. 
Prior to the FA-PAMAM conjugation, the surface of SPIONs was modified to create 
14 
 
 
the activated carboxyl groups (Fig 2). The fabrication process includes three main 
steps: amine functionalization, carboxylation, and FA-PAMAM conjugation. 
 
Figure 2. SPIONs decorated FA-PAMAM (SPIONs@FA-PAMAM) 
fabrication process. 
2.3.1. Amine functionalized SPIONs (SPIONs@APTS) 
Synthesized SPIONs were functionalized by (3-aminopropyl) 
trimethoxysilane (APTS) to have peripheral amino groups [78–80]. Briefly, 1g of 
SPIONs were dispersed in 300 ml EtOH with probe sonication for 1 h. Then 6 ml 
of APTS was added to the EtOH solution. The solution was sonicated for another 
1 h. The resulting product SPIONs@APTS were precipitated using a strong 
neodymium N52 magnet and then the reaction mixture was decanted. The product 
was washed 3 times by dispersing in 300 ml EtOH with probe sonication, followed 
by magnet decantation. SPIONs@APTS were dried under vacuum on a rotary 
evaporator. Energy dispersive X-ray spectroscopy (EDS) and FTIR spectroscopy 
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were used to characterized the product. Size and zeta potential were measured by 
Beckman Coulter Delsa Nano instrument. 
2.3.2. Carboxylation of amine functionalized SPIONs (SPIONs@COOH) 
Succinic anhydride was used to carboxylate the amine groups of 
SPIONs@APTS according to previously reported study [81]. Briefly, 100 mg of 
SPIONs@APTS were dispersed in 150 ml EtOH using probe sonication. Succinic 
anhydride (500 mg) was added to 150 ml of DMSO under vigorous stirring and 
then added to the SPIONs@APTS in EtOH solution. The reaction was stirred at 
RT for 24 h. The resulting product SPIONs@COOH were precipitated using a 
strong neodymium N52 magnet, followed by the decantation of the supernatant. 
The product SPIONs@COOH were washed 3 times by dispersing in 300 ml EtOH 
using probe sonication, followed by decantation, and were dried under vacuum on 
a rotary evaporator. The product was confirmed by FTIR spectroscopy, size, and 
zeta potential measurements. 
2.3.3. Activation of SPIONs@COOH and fabrication of FA-PAMAM and 
SPIONs@COOH conjugate 
Carboxyl groups of SPIONs@COOH were activated using carbodiimide 
reaction. In brief, 50 mg of SPIONs@COOH were dispersed in 100 ml DMSO using 
probe sonication for 1 h. Then, 490 mg EDC and 735 mg NHS were added to the 
solution. The reaction was left for 24 h under vigorous stirring. Activated 
SPIONs@COOH were conjugated with 100 mg PAMAM or 100 mg FA-PAMAM 
(dissolved in DMSO) to have SPIONs@PAMAM or SPIONs@FA-PAMAM. The 
final products SPIONs@PAMAM and SPIONs@FA-PAMAM were purified by 
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precipitation by a strong neodymium N52 magnet, followed by decantation of the 
supernatant. The products were washed 3 times by dispersing in 300 ml EtOH and 
followed by magnet decantation. The products were characterized by size and zeta 
potential measurements. 
To quantify the amount of dendrimers conjugated to SPIONs, PAMAM 
dendrimers, and FA-PAMAM conjugates were labeled with Rhodamine B 
isothiocyanate according to previously reported method [82]. In short, PAMAM or 
FA-PAMAM conjugates were dispersed in 50 ml EtOH. Rhodamine B 
isothiocyanate was added to the EtOH dispersion. The amount of Rhodamine B 
isothiocyanate was calculated to have the ratio of Rhodamine B isothiocyanate to 
PAMAM or FA-PAMAM of 3:1. The reaction was stirred at RT for 1h, and followed 
by dialysis in 5L of DIW for 3 times with the molecular weight cut-off 3.5 kDa. 
Lyophilization was performed at the end of the dialysis to have the dry powder of 
Rhodamine B label PAMAM (RhoB-PAMAM) and Rhodamine B labeled FA-
PAMAM (RhoB-FA-PAMAM). Fluorescence spectroscopy was employed to 
measure the fluorescence of the Rhodamine B labeled formulations 
(SPIONs@RhoB-PAMAM and SPIONs@RhoB-FA-PAMAM). The amounts of 
PAMAM and FA-PAMAM conjugated to SPIONs were calculated based on the 
linear equation of Rhodamine B fluorescence and Rho B-PAMAM or Rho B-FA-
PAMAM concentrations. 
2.3.4. Transmission electron microscopic analysis 
The size of the synthesize SPIONs and the fabricated product 
SPIONs@PAMAM and SPIONs@FA-PAMAM were studied using transmission 
17 
 
 
electron microscopy. Samples were prepared according to a previous method [72]. 
Briefly, 4 µL of each sample (dispersion of 2 mg powder of the sample in 5 ml of 
DIW) was applied to a Formvar-coated, carbon-stabilized copper grid (400 mesh). 
The copper grid was air-dried and negatively stained with 5% aqueous uranyl 
acetate, and was allowed to dry. Samples were analyzed by JEOL Transmission 
electron microscope equipped with LaB6 filament gun (JEM 2010, Tokyo, Japan) 
at an accelerating voltage of 200 kV. 
2.4. CDF encapsulation 
Anticancer drug CDF was encapsulated in SPIONs@PAMAM and 
SPIONs@FA-PAMAM separately using equilibrium dialysis method as described 
earlier [72,83]. Briefly, CDF and SPIONs formulations were calculated to have CDF 
and dendrimer (PAMAM or FA-PAMAM) at the molar ratio of 50:1. Both CDF and 
SPIONs@PAMAM or SPIONs@FA-PAMAM were dissolved in the mixture of 
DMSO and phosphate buffered saline (PBS) pH 7.4 (ratio 4:6). The mixed solution 
was stirred in the dark at a low speed of 50 rpm for 72h at RT. The CDF 
encapsulated SPIONs@PAMAM-CDF and SPIONs@FA-PAMAM-CDF were 
precipitated using a strong neodymium N52 magnet. The supernatant was used 
for indirect drug loading method. After decantation, the formulations were washed 
by dispersing in 100 ml EtOH by vortexing, followed by magnet decantation. Dry 
products were obtained by drying under vacuum on a rotary evaporator. 
The remaining CDF in the supernatant after drug loading was determined 
by High-performance liquid chromatography (HPLC) method using a C18 column 
with photodiode array detector (PDA) at 447 nm.  For the remaining CDF 
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concentration determination, a standard curve of CDF was made by dissolving 
known amounts of CDF in DMSO and its successive dilutions in the mobile phase, 
followed by HPLC analysis at the absorbance of 447 nm. A known amount of the 
supernatant containing unloaded CDF was diluted in DMSO, followed by further 
dilution in the mobile phase and HPLC analysis at the absorbance of 447 nm. The 
amount of remaining CDF was calculated based on the CDF standard curve, and 
the percentage of CDF loaded in the formulations were calculated based on the 
subtraction of the initial amount of CDF and the remaining amount of CDF. 
2.5. Fluorescence microscopy study 
Fluorescence microscopic study was performed in SKOV3 cells to compare 
the targeting ability of SPIONs@FA-PAMAM and SPIONs@PAMAM. In brief, 
SKOV3 cells were seeded in a four-well chamber slide (5 x 104 cells in each well) 
and incubated at 37oC in a 5% CO2 air humidified atmosphere for 24 h. The 
medium was removed and Rhodamine B labeled formulations (SPIONs@PAMAM-
Rho and SPIONs@FA-PAMAM-Rho) were added and incubated for 6 h. The 
formulation containing medium was removed, and cells were washed for 3 times 
with cold PBS (pH 7.4), and fixed with 3% formaldehyde in the PBS pH 7.4 at RT 
for 10 min. Samples were analyzed qualitatively using a fluorescent microscope 
(Leica, Germany) [84]. 
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2.6. T2 relaxivity and in vitro relaxometry and imaging studies 
2.6.1. T2 relaxivity studies of SPIONs, SPIONs@PAMAM, and 
SPIONs@FA-PAMAM 
T2 relaxometry was performed using a 7.0 T Bruker ClinScan system. The 
instrumental parameters wecre set as follows: a 7.0 T magnetic field strength, pixel 
spacing at 0.297/0.297, repetition time 2000 ms, echo time 11 ms, and slice 
thickness of 2 mm. Synthesized SPIONs and their modification SPIONs@PAMAM 
and SPIONs@FA-PAMAM were analyzed at different iron concentrations 10, 20, 
40, 60, 80, and 100 μg/ml. The T2 relaxivity was calculated from the linear slope of 
the inverse T2 (1/T2) relaxation time according to the iron concentration. 
2.6.2. In vitro MR relaxometry and imaging 
5 x 105 HeLa and SKOV3 cells were incubated with both the non-targeted 
formulation SPIONs@PAMAM and the targeted formulation SPIONs@FA-
PAMAM at iron concentrations of 10,20,40, and 80 μg/ml for 30 min at 4oC 
according to the previously reported method [59]. In short, 5 x 105 HeLa and 
SKOV3 cells were trypsinized and suspended in cold PBS (in an ice bath) and 
incubated with the formulations. After 30 min incubation, cells were centrifuged 
down at 800 rpm for 3 min to form a pellet. Cells were washed 3 times with cold 
PBS to remove free particles. Final pellets were resuspended in cold PBS and 
used for MR imaging. A phantom was constructed consisting of all of the sample 
vials. The instrumental parameters were set a 7.0 T magnetic field strength, pixel 
spacing at 0.297/0.297, repetition time 2000 ms, echo time 11 ms, and slice 
thickness of 2 mm. 
20 
 
 
2.7. In vitro cytotoxicity study 
The in vitro cytotoxicity of free CDF, SPIONs@PAMAM-CDF, and 
SPIONs@FA-PAMAM-CDF formulations were evaluated by MTT assay on HeLa 
and SKOV3 cell lines. In brief, HeLa and SKOV3 cells were seeded in 96 well-
plates with an average of 3000 cells in each well. After 24 h incubation at 37oC in 
a 5% CO2 air humidified atmosphere, cells were treated with various formulations 
with a concentration range from 0.25 μM to 5 μM. Treated cells were incubated for 
72 h at 37oC followed by addition of MTT solution (1mg/ ml) and further incubation 
at 37oC for 3h. Then, the media was replaced by DMSO (100 μl in each well). The 
absorbance was measured at 590 nm using a high-performance multi-mode plate 
reader Synergy 2 (BioTek). The percentage of viable cells was determined by 
comparing the absorbance with appropriate controls [7,13]. 
2.8. Folate receptor blocking assay 
The folate receptor blocking assay was performed to understand the 
mechanism by which the targeting SPIONs@FA-PAMAM-CDF internalize HeLa 
and SKOV3 cells via folate receptor mediated endocytosis. This assay is based on 
the principle of the initial blockade of folate receptors of HeLa and SKOV3 by 
adding an excess amount of free FA (1 mM) [72], followed by treatment with 
formulations (CDF, SPIONs@PAMAM-CDF, and SPIONs@FA-PAMAM-CDF).  
The cell viability of HeLa and SKOV3 were determined by MTT assay after 72 h 
incubation at 37oC. This assay is performed according to the previously reported 
protocol [85]. In short, HeLa and SKOV3 cells were seeded in 96 well-plates for 24 
h, followed by addition of 100 μl of 1mM FA in each well and incubation at 37oC 
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for 3 h. Then, cells were washed twice with PBS (pH 7.4), followed by media and 
addition of formulations. After 72 h incubation at 37oC, MTT assay was performed 
to determine the cell viability as stated in the previous section. 
2.9. Apoptosis assay by flow cytometry 
Apoptosis assay was performed on HeLa cell line according to our previous 
study [72]. In brief, HeLa cells were cultured in 6-well plates at 5x104 cells in each 
well and incubated for 24 h at 37oC under 5% CO2, followed the treatment of plain 
CDF, SPIONs@PAMAM-CDF, and SPIONs@FA-PAMAM-CDF to induce 
apoptosis. The concentration of CDF, SPIONs@PAMAM-CDF and SPIONs@FA-
PAMAM-CDF were chosen based on the IC50 value of CDF on HeLa cells from the 
in vitro cytotoxicity assay. After 72h incubation, cells were collected and the sample 
was prepared according to the protocol for Guava Nexin Annexin V assay (EMD 
Millipore, USA). In short, media and trypsinized treated cells were collected in 15 
ml tubes and centrifuged at 300 x g for 7 min. Cell pellets were dispersed in PBS 
pH 7.4 with 1% FBS to have the number of cells in the range of 2 x 105 – 1 x 106 
cells/mL. Then 100 μL of cell dispersion of each sample was added 100 μL of the 
Guava Nexin Reagent and was incubated for 20 min at RT in the dark. The 
samples were analyzed by Guava Easycyte flow cytometer (EMD Millipore, USA). 
2.10. Western blot 
Western blot analysis was performed to determine the level expression of 
Phosphatase and tensin homolog PTEN and Nuclear factor kappa B (NF-κB) in 
HeLa cell line using reported method [86]. Briefly, HeLa cells were treated with 
different formulations as well as free CDF and lysed. The protein concentration 
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was determined by the Bio-Rad Protein Assay (Bio-Rad kit). Lysates were 
electrophoresed by SDS-PAGE and the proteins were transferred onto the 
nitrocellulose blotting membrane, followed by blocking with 5% BSA in TBST buffer 
at RT for 1h. Primary PTEN or NF-κB antibodies were added and incubated 
overnight at 4oC, subsequently washed and incubated with compatible secondary 
antibodies. The protein bands were visualized by incubation with 
chemiluminescent substrate (Thermos scientific) at room temperature for 2 min, 
followed by chemiluminescent detection using a digital imaging system 
ImageQuant LAS 4000 (GE Healthcare Bio-Sciences AB, Sweden).  
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CHAPTER 3 RESULTS 
A vast majority of cancer cells are known to have a high expression of folate 
receptors, while normal tissues and organs have very limited expression of folate 
receptors [87]. Many studies have shown an enhance in anticancer activity 
employing folic acid decorated nanocarriers in different cancer types such as 
ovarian, lung, cervical, breast, kidney, colorectal, epithelial and brain cancers 
[85,88–90]. CDF has been shown a high anticancer activity against various types 
of cancers as well as overcome drug resistance [11,86]. However, extremely low 
aqueous solubility of CDF makes its systemic administration problematic. Our 
previous study suggested that PAMAM dendrimer conjugated with folic acid could 
improve the aqueous solubility of CDF dramatically and gave the active targeting 
with an enhanced anticancer activity due to the folate receptor mediated 
endocytosis [72]. In addition, many studies reported the potential usage in 
biomedical imaging of PAMAM dendrimers when fabricated with magnetic iron 
oxide nanoparticles [59,78,91–93]. Based on these information, the goal of this 
present work was to design a theranostic nanoparticles consisting of FA-PAMAM 
conjugate as the outer shell and iron oxide nanoparticles as the inner core loaded 
with CDF which could be used in both cancer imaging and therapy for multiple 
cancers. 
3.1. SPIONs synthesis and characterization 
The magnetic iron oxide nanoparticles SPIONs were synthesized by 
controlled co-precipitation of Fe2+ and Fe3+ ions according to previously reported 
method [77,94,95]. The synthesized SPIONs were confirmed by FTIR 
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spectroscopy. The presence of Fe3O4 core was identified by the strong stretching 
absorption band between 408 and 673 cm-1 corresponding to the Fe-O bond of the 
particles (Fig. 3a) [78]. Dynamic light scattering technique measurement showed 
a hydrodynamic size of 78.8 nm (PDI 0.177) and a zeta potential at – 59.73 mV 
(Fig. 3d). 
 
Figure 3. (a) FTIR spectra of SPIONs, SPIONs@APTS, and 
SPIONs@COOH; (b) Energy dispersive X-ray spectroscopy (EDS) analysis of 
SPIONs@APTS; (c) Hydrodynamic size of the fabricated nanoparticles 
SPIONs@PAMAM and SPIONs@FA-PAMAM; and (d) Zeta potential 
measurement of each step of the fabrication process are shown. 
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3.2. FA-PAMAM decorated SPIONs fabrication and 
characterization 
3.2.1. Amine functionalized SPIONs (SPIONs@APTS) 
The sonication time was optimized according to previous reported method 
[78]. Sonication of the synthesized SPIONs before modification with APTS 
improved the magnetic properties and size distribution of the particles. After 
aminosilane modification of the SPIONs, the achieved product SPIONs@APTS 
could be dispersed back in DIW to form a stable dispersion with a hydrodynamic 
size of 95.9 nm (PDI 0.113). SPIONs@APTS showed a zeta potential of 56.94 mV 
confirming the presence of the positively charged amine groups of APTS (Fig 3d). 
Energy-dispersive X-ray spectroscopy (EDX) spectrum showed the unique peak 
of Si further confirmed the successful coating of the aminosilane APTS on the 
surface of SPIONs (Fig 3b). FTIR spectrum confirmed the presence of APTS on 
the surface of SPIONs with the characteristic peaks of C-H at 2888, 2979 cm-1, Si-
C at 1330 cm-1, Si-O at 1049 cm-1, and Fe-O at 574 cm-1 (Fig. 3a). 
3.2.2. Carboxylation of amine functionalized SPIONs (SPIONs@COOH) 
The carboxylation of primary amine groups on the surface of 
SPIONs@APTS was confirmed by the change in zeta potential from a positive 
charge of 56.94 mV (of the amine groups) to a negative charge of -63.22 mV (of 
the carboxyl groups) (Fig 3d). FTIR spectrum of SPIONs@COOH showed the 
characteristic peaks of C-H bond at 2981 cm-1 and 2862 cm-1, Si-O bond at 
1045cm-1, Fe-O bond at 571 cm-1, and the C=O stretching at 1700 cm-1 (Fig. 3a). 
SPIONs@COOH had a hydrodynamic size of 96.2 nm (PDI 0.246). 
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3.2.3. Activation of SPIONs@COOH and fabrication of FA-PAMAM and 
SPIONs@COOH conjugate 
Zeta potential was used to confirmed the conjugation of PAMAM and FA-
PAMAM to the activated SPIONs@COOH. Before conjugation, SPIONs@COOH 
had the zeta potential of -63.22 mV. After the conjugation, the zeta potential values 
were changed to 48.79 mV and 9.97 mV in case of SPIONs@PAMAM and 
SPIONs@FA-PAMAM, respectively (Fig. 3d). Dynamic light scattering showed an 
average size of 110.1 nm (PDI 0.125) and 159.4 nm (PDI 0.127) of 
SPIONs@PAMAM and SPIONs@FA-PAMAM, respectively (Fig 3c). 
Fluorescence spectroscopy measurement showed an average of 20.37% (wt/wt) 
of PAMAM in SPIONs@PAMAM, and 27.61% (wt/wt) of FA-PAMAM conjugates in 
SPIONs@FA-PAMAM structure. 
3.2.4. Transmission electron microscopic analysis 
To further determine the size of the nanoformulations, electron microscopic 
analysis of the synthesized SPIONs, and the carrier SPIONs@PAMAM and 
SPIONs@FA-PAMAM was performed. TEM images showed that the morphology 
of the fabricated SPIONs was remained the same as the unmodified SPIONs. TEM 
data showed that the inner SPIONs core had the average size of 11 nm confirming 
the nano-metric size of the formulations (Fig. 4). 
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Figure 4. Transmission electron microscopic images of SPIONs, 
SPIONs@PAMAM and SPIONs@FA-PAMAM show the morphology of the 
fabricated nanoparticles. 
3.3. CDF drug loading in nanoparticles 
The CDF drug loading was studied based on the indirect method. The 
remaining of CDF in the supernatant after drug loading was measured by HPLC 
method. A calibration curve of CDF was developed from 10 μg/ml to 250 μg/ml 
with the R2 value of 0.99. The HPLC method was validated for its accuracy and 
precision and was used to determine the CDF concentration. The loading of CDF 
in SPIONs@PAMAM and SPIONs@FA-PAMAM was 12.37% (wt/wt) and 9.81% 
(wt/wt), respectively. 
3.4. Fluorescence microscopy study 
SKOV3 cells were selected for in vitro fluorescence microscopic study 
based on the results of in vitro cytotoxicity assay and receptor blocking assay to 
compare the level of cellular internalization of the non-targeted formulation 
SPIONs@PAMAM-CDF and the targeted formulation SPIONs@FA-PAMAM-CDF. 
In this cell uptake studies, SKOV3 cells were incubated with Rhodamine B (having 
red fluorescence) labeled nanoformulations and analyzed after 6 hours of 
incubation at 37oC in the dark. As shown in figure 5, SKOV3 cells treated with both 
of the non-targeted and the targeted formulations showed apparent fluorescence. 
As compared to the non-targeted formulation, there was a significantly higher 
fluorescence in cells treated with targeted formulations. 
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Figure 5. Fluorescence microscopic images (40X) of SKOV3 cells 
incubated with nuclear stain Hoechst (blue fluorescence) and Rhodamine B (red 
fluorescence) labeled non-targeted SPIONs@PAMAM and targeted formulations 
SPIONs@FA-PAMAM at 6 h are shown. 
3.5. T2 relaxivity and in vitro relaxometry and imaging studies 
3.5.1. T2 relaxivity studies of SPIONs, SPIONs@PAMAM and 
SPIONs@FA-PAMAM 
T2 relaxivity studies were performed to examine the magnetic behavior of 
the synthesized SPIONs and the nano-carrier SPIONs@PAMAM and 
SPIONs@FA-PAMAM in their biomedical application in MR imaging. The potential 
of the fabricated magnetic nanoparticles SPIONs@PAMAM and SPIONs@FA-
PAMAM to be used as T2-based contrast agent for MR imaging was evaluated 
using the measured transverse relaxation time (T2) of SPIONs@PAMAM and 
SPIONs@FA-PAMAM as compared to SPIONs. The T2 values were used to 
calculate the transverse relaxivity rate (r2) per μg/ml of iron, which showed the 
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efficiency of the fabricated nanoparticles as a MR contrast agent. From figure 6a, 
there was a significant decrease in the signal intensity of the T2-weighted MR 
images with the increase of iron concentration in both of the non-targeted 
SPIONs@PAMAM and the targeted SPIONs@FA-PAMAM nanoparticles as 
compared to the control PBS. Pseudo-color MR images showed a decrease in 
signal intensity for the fabricated nanoparticles from red (high intensity) to purple 
(low intensity). The T2 relaxation rate (1/T2) increased linearly with the iron 
concentration (μg/ml) in both cases of the non-targeted SPIONs@PAMAM and the 
targeted SPIONs@FA-PAMAM nanoparticles. The slope values (r2) were 
calculated to be 1.92 (μg/ml)-1s-1 and 1.81(μg/ml)-1s-1 in case of SPIONs@PAMAM 
and SPIONs@FA-PAMAM, respectively.  Unmodified SPIONs had the slope value 
(r2) of 2.01 (μg/ml)-1s-1. The results suggested that both of the non-targeted 
nanoparticle SPIONs@PAMAM and the targeted nanoparticle SPIONs@FA-
PAMAM could be used as T2-shortening agents. 
3.5.2. In vitro MR relaxometry and imaging studies 
In vitro MR relaxometry and Imaging studies were performed to examine 
the effect of the targeting ability of folate-based nanoparticle SPIONs@FA-
PAMAM in MR imaging. To study the effect of SPIONs@PAMAM and 
SPIONs@FA-PAMAM on SKOV3 and HeLa cells, we measured the T2 of SKOV3 
and HeLa cells after incubation with different concentration of SPIONs@PAMAM 
and SPIONs@FA-PAMAM for 30 min. There was a significant decrease in signal 
intensity in SKOV3 and HeLa cells when incubated with the targeted nanoparticle 
SPIONs@FA-PAMAM. In contrast, non-targeted nanoparticle SPIONs@PAMAM 
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showed a very little decrease in the signal intensity in both SKOV3 and HeLa cells. 
In the T2-weighted MR images, targeted formulation SPIONs@FA-PAMAM at the 
iron concentration of 80 μg/ml decreased the MR signal intensity to 45.6% in 
SKOV3 and 28% in HeLa, as compared to 100% of PBS control. However, non-
targeted nanoparticle SPIONs@PAMAM at the iron concentration of 80 μg/ml 
showed a lower decrease in MR signal intensity with 87% in SKOV3 and in 71.4% 
HeLa, as compared to 100% of control PBS (Fig 6b). 
 
Figure 6. (a) T2-weighted MR images of the aqueous dispersion of 
SPIONs@PAMAM and SPIONs@FA-PAMAM with the T2 relaxation rate (1/T2) as 
a function of iron concentration indicating the ability of the fabricated nanoparticles 
to enhance the contrast in MR images; (b) MR images of SKOV3 and HeLa cell 
pellets after 30 min incubation with the non-targeted SPIONs@PAMAM and the 
targeted SPIONs@FA-PAMAM nanoparticles (with the color change from red to 
purple indicating the gradual decrease of MR signal intensity). The percentage of 
signal intensity compared to cells in PBS was plotted as a function of iron 
concentration indicating the faster internalization with a higher decrease in MR 
signal intensity of the targeted SPIONs@FA-PAMAM. 
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3.6. In vitro cytotoxicity study 
In vitro cytotoxicity of the CDF loaded nanoformulations was examined in 2 
cell lines [SKOV3 (human ovarian carcinoma cell line), HeLa cells (human cervical 
cancer cells)] with a broad range of CDF concentrations (0.25 µM - 5 µM). Plain 
targeted carrier (SPIONs@FA-PAMAM) showed negligible cytotoxicity with cell 
viability more than 90% confirming the safety of the targeted carrier. The 
anticancer activity of the nanoformulations (non-targeted formulation 
SPIONs@PAMAM-CDF and targeted formulation SPIONs@FA-PAMAM-CDF) 
was studied and compared with free drug CDF. The results showed a dose-
dependent cell killing for both SPIONs@PAMAM-CDF and SPIONs@FA-PAMAM-
CDF. The outcome of the study revealed an IC50 (half maximal inhibitory 
concentration) of 0.45 µM, 0.78 µM, and 1.79 µM for free CDF, SPIONs@FA-
PAMAM-CDF, and SPIONs@PAMAM-CDF, respectively in SKOV3 cells. The 
noticeably lower IC50 of the targeted SPIONs@FA-PAMAM-CDF as compared to 
the non-targeted SPIONs@PAMAM-CDF was probably due to the folate receptor-
specific targeting of SPIONs@FA-PAMAM-CDF. The same pattern was also 
observed in HeLa cells with the IC50 of 0.66 µM, 0.87 µM, and 1.98 µM for free 
CDF, SPIONs@FA-PAMAM-CDF, and SPIONs@PAMAM-CDF, respectively (Fig. 
7a). 
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Figure 7. (a) In vitro cytotoxicity assay showing percentage of cell viability 
observed at 72 h after treating SKOV3 and HeLa cells with various formulations 
are shown (n=8); (b) MTT assay observed at 72 h after folate receptor blocking 
and treating of SKOV3 and HeLa cells with SPIONs@PAMAM-CDF and 
SPIONs@FA-PAMAM-CDF are shown (n=8); (c) Induction of apoptosis in HeLa 
cells when treated with CDF, SPIONs@PAMAM-CDF, and SPIONs@FA-PAMAM-
CDF as evaluated by Annexin V/7-AAD dual staining. An increased percentage of 
the apoptotic cell population was noted when cells were treated with targeted 
formulation (SPIONs@FA-PAMAM-CDF) as compared to the non-targeted 
formulation (SPIONs@PAMAM-CDF), suggesting the better killing activity of the 
targeted formulation SPIONs@FA-PAMAM-CDF. 
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3.7. Folate receptor blocking assay 
Folate receptor blocking assay was performed to examine the fate of the 
folate-based targeting formulation. SKOV3 and HeLa cells with high expression of 
folate receptors were treated with an excess amount of FA (1 mM) to overwhelm 
the folate receptor binding domains on the cell membrane, followed by the 
treatment with the nanoformulations [73–76,96]. In vitro cytotoxicity MTT assay 
was used to determine the change in the cell viability in SKOV3 and HeLa treated 
with the formulations after blocking the folate receptors. It was observed that 
before blockade of folate receptors, the IC50 values on SKOV3 were 0.80 µM and 
1.81 µM for the targeted SPIONs@FA-PAMAM-CDF and the non-targeted 
SPIONs@PAMAM-CDF, respectively. After the blockade of folate receptors, the 
IC50 value of the targeted SPIONs@FA-PAMAM-CDF was increased to 1.36 µM. 
However, there was not a significant change in the IC50 of the non-targeted 
SPIONs@PAMAM-CDF (1.82 µM). The same outcome was observed in HeLa 
cells with the IC50 of 0.85 µM and 2 µM for SPIONs@FA-PAMAM-CDF and 
SPIONs@PAMAM-CDF, respectively before the folate receptor blockade. After 
blocking folate receptors, the IC50 values were found to be 1.26 µM and 1.94 µM 
for SPIONs@FA-PAMAM-CDF and SPIONs@PAMAM-CDF, respectively. The 
results suggested a decrease in anticancer activity of the targeted formulation 
SPIONs@FA-PAMAM-CDF in SKOV3 cells when folate receptors are blocked 
(Fig. 7b). 
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3.8. Apoptosis assay 
HeLa cells were selected for this apoptosis assay. Apoptosis induction in 
HeLa cells of free CDF and the CDF loaded formulations was determined by flow 
cytometry with Annexin V/7-AAD dual staining. The percentage of Annexin V-/7-
AAD - (R5), Annexin V+/7-AAD - (R6) and Annexin V-/7-AAD + (R4) and Annexin V-
/7-AAD + (R3) were used to determine the number of live cells, early apoptotic, late 
apoptotic and necrotic cells. Apoptosis assay revealed a higher percentage of 
apoptotic and necrotic HeLa cells (34.2 ± 3.2 %) after treatment with the targeted 
formulation SPIONs@FA-PAMAM-CDF. Non-targeted formulation showed a lower 
number of apoptotic and necrotic cells at 20.5 ± 2.7 % of the cell population. The 
results suggested a higher apoptosis induction ability of the targeted formulation 
SPIONs@FA-PAMAM-CDF as compared to the non-targeted formulation 
SPIONs@PAMAM-CDF (Fig. 7c). The results were consistent with higher 
anticancer activity of the targeted formulation SPIONs@FA-PAMAM-CDF in in 
vitro cytotoxicity assay using MTT with higher cellular uptake in fluorescence 
microscopic studies and in vitro relaxometry and imaging studies. 
3.9. Western blot 
Western blot was performed to examine the level expression of PTEN and 
NF-κB in HeLa cells after treatment with the nanoformulations. In case of NF-κB, 
control HeLa cells without treatment showed a higher expression of NF-κB as 
compared to HeLa cells treated with plain CDF and the nanoformulations. 
Targeted formulation SPIONs@FA-PAMAM-CDF showed a slightly better 
downregulation of NF-κB (76.4 ± 4.6 % as of control) as compared to the non-
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targeted formulation SPIONs@PAMAM-CDF (83.6 ± 8.2 % as of control). In case 
of PTEN expression, the control HeLa cells without treatment showed a 
significantly low expression of PTEN. However, after treatment with plain CDF and 
nanoformulations, PTEN expression was elevated. Noticeably, in comparison to 
control, HeLa cells treated with the targeted formulation SPIONs@FA-PAMAM-
CDF showed the highest upregulation of PTEN expression (319.9 ± 27.1 %) as 
compared to free CDF (158.9 ± 13.5 %) and the non-targeted formulation 
SPIONs@PAMAM-CDF (214.2 ± 10.9%) (Fig. 8). 
 
 
Figure 8. Western blot analysis showing PTEN and NF-κB expression in HeLa 
cells in control without treatment (CTL), and cells treated with CDF, targeted 
formulation SPIONs@FA-PAMAM-CDF (T) and non-targeted formulation 
SPIONs@PAMAM-CDF (NT), (GAPDH expression was used as the protein 
loading control).  
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CHAPTER 4 DISCUSSION 
The bleak prognosis for patients diagnosed with metastatic cancer along 
with the high costs of treating cancer in its advanced stages are urging for a better 
predictive and preventative method [97]. With the advantages of noninvasive MR 
imaging with superb spatial resolution, targeting MRI contrast agents are believed 
to be critical tools which can fully benefit from this new technique [98,99]. The 
targeting ability of MRI contrast agents depends strongly on their ability to carry 
specific molecular markers for tumor recognition. As a result, the tumor can be 
visualized and diagnosed earlier accurately leading to an effective treatment, and 
ultimately improving patient survival [37,98]. In this regards, PAMAM dendrimers 
with the ability to conjugate targeting ligands through numerous peripheral reactive 
amine groups have been studied recently for surface modification of iron oxide 
nanoparticles for targeting MRI [78,100,101]. In terms of targeting ligands, folic 
acid recently has received considerable attention as a targeting ligand to target 
folate receptors overexpressed on numerous types of tumors [89,90,96,102–106]. 
PAMAM dendrimers conjugated folic acid can take advantage of the favorable 
binding of targeting ligand folic acid to folate receptors on tumor cells to enhance 
the cellular uptake via folate receptor mediated endocytosis. Many studies have 
shown that iron oxide nanoparticles decorated with folate-based PAMMA 
dendrimer could achieve MRI targeting with higher cellular internalization in cancer 
cells with a higher contrast in T2-weighted MR images [59,71,78]. However, in most 
of the studies, the ability of PAMAM dendrimers in drug delivery was not fully 
examined. 
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The poor aqueous solubility of several potent anticancer compounds could 
be a major issue and deciding factor in realizing its translation potential from the 
bench to the bedside. The non-specific distribution of chemotherapeutic agents in 
the systemic circulation gives the conventional chemotherapy a low therapeutic 
index and severe side effects which cause the treatment to be ineffective and lead 
to the recurrence of tumor after initial treatment. Recently, CDF has been shown 
to be a very potent anticancer compound with the ability to treat different types of 
cancers [12,13,72]. However, low solubility profile of CDF makes its systemic 
administration problematic. In this regard, PAMAM dendrimers have revealed 
promising potentials. Our earlier reported study suggested that folate-decorated 
PAMAM dendrimers could encapsulate CDF in their hydrophobic cavities for 
aqueous solubility enhancement and deliver CDF specifically to the tumor site with 
minimizing adverse side effects [72]. The aim of this study was to design a 
theranostic carrier consisting of iron oxide nanoparticles with folate-based PAMAM 
dendrimers for active targeting MR imaging and anticancer drug delivery. As a 
result, the targeted nanoparticles SPIONs@FA-PAMAM can enhance the aqueous 
solubility of CDF and deliver it specifically to cancer cells with a higher contrast in 
T2-weight MR images. 
The synthesis of SPIONs was confirmed by FTIR spectrum with the 
characteristic peak of Fe-O at 574 cm-1. The synthesized SPIONs could be 
dispersed back in DIW or EtOH to form a stable dispersion with a hydrodynamic 
size of 78.8 nm (PDI 0.177) and a zeta potential of -59.73 mV. TEM images of 
SPIONs showing an average size at 10.5 ± 1 nm further reconfirmed the success 
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of the synthesis. Surface modification of SPIONs was confirmed by zeta potential 
with a change from an initial zeta potential of -59.73 mV of SPIONs to 56.94 mV 
of SPIONs@APTS, and -63.22 mV of SPIONs@COOH (Fig 3d). In EDX analysis 
of SPIONs@APTS, the atomic ratio of Fe/Si was shown to be 17.55/1 (Fig. 3b). 
The mathematic calculation was used to estimate the number of silanes per gram 
particles according to the reported method [77]. From TEM images, synthesized 
SPIONs were shown to have an average diameter (rSPIONs) of 5.5 nm; therefore, 
the surface area (SASPIONs) of one particle is 380 nm2 (SASPIONs = 4πrSPIONs2). One 
silane is known to cover an approximately 0.4 nm2 of the particle’s surface area, 
so we have an average of 950 silanes covered the surface of one SPION [77]. 
With the atomic ratio 17.55/1 of Fe/Si in SPIONs@APTS from EDX analysis, it is 
estimated that 950 silanes would cover one particle with an average of 16,672.5 
iron atoms. Therefore, 1 g of SPIONs would have an average of 0.099 g of APTS 
coating, theoretically. 
PAMAM and FA-PAMAM conjugation was confirmed by a change in zeta 
potential. After conjugation, SPIONs@PAMAM and SPIONs@FA-PAMAM had a 
zeta potential of 48.79 mV and 9.97 mV, respectively (Fig. 3d). FA conjugation 
helped the targeted carrier SPIONs@FA-PAMAM reduce the highly positive 
charge, which is known to be associated with the toxicity of PAMAM dendrimers 
[16]. The morphology of nanoparticles could be affected by several factors 
including the fabrication and reaction involved. The shape and size of 
nanoparticles could have a high impact on their biodistribution, clearance, and 
biocompatibility [107]. TEM images suggested that the morphology of the particles 
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remained unchanged after the fabrication. Dynamic light scattering measurement 
showed that both of the non-targeted and targeted formulations were in the nano-
sized range with an average hydrodynamic size of 110.1 nm (PDI 0.125) and 159.4 
nm (PDI 0.127) of SPIONs@PAMAM and SPIONs@FA-PAMAM, respectively (Fig 
3c). A higher value in hydrodynamic size of SPIONs@FA-PAMAM could be 
attributed to the presence of FA resulting in a low positive charge of the particles. 
Drug loading studies showed a little higher in CDF encapsulation in SPIONs@FA-
PAMAM-CDF as compared to SPIONs@PAMAM-CDF. The presence of FA might 
be responsible for a higher drug loading with a shielding effect outside the 
hydrophobic cavities; thus, a higher amount of CDF was encapsulated inside the 
hydrophobic cavities. 
Targeting ability of folate-decorated nanoformulations was examined in 
fluorescence microscopic study on SKOV3 cell line. SKOV3 cells treated with 
Rhodamine B labeled targeted formulation SPIONs@FA-PAMAM-CDF showed a 
significantly higher red fluorescence intensity of Rhodamine B dye as compared to 
the Rhodamine B labeled non-targeted formulation SPIONs@PAMAM. The 
fluorescence microscopic images were taken after only 6 h incubation of SKOV3 
cells with the Rhodamine B labeled formulations, which proved the ability of the 
targeted formulation to internalize the cells within such a short time frame [Fig 5]. 
The magnetic behavior of the non-targeted SPIONs@PAMAM and the 
targeted SPIONs@FA-PAMAM was examined in the T2 relaxivity studies to test 
their ability to enhance the contrast in MR images [Fig 6]. The T2 relaxation rate 
(1/T2) as a function of the iron concentration (from 10 μg/ml to 40 μg/ml) of both of 
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the carriers showed that the relaxation rate increases linearly with the iron 
concentration with a slope (r2) of 1.92 (μg/ml)-1s-1 and 1.81(μg/ml)-1s-1 for 
SPIONs@PAMAM and SPION@FA-PAMAM, respectively. The slightly lower r2 of 
SPIONs@FA-PAMAM may be due to the presence of FA on the periphery of the 
particles, which shields water molecules from accessing the surface of SPIONs. 
The results suggested that SPIONs@PAMAM and SPIONs@FA-PAMAM could 
be used as T2-shortening agents which helped enhance the contrast in the MR 
images. To study the effect of the non-targeted SPIONs@PAMAM and the 
targeted SPIONs@FA-PAMAM on the MR images of SKOV3 and HeLa cells, T2 
of SKOV3 and HeLa cells was measured after 30 min incubation with various 
concentrations of SPIONs@PAMAM and SPIONs@FA-PAMAM. The T2 values of 
SKOV3 and HeLa cell pellets treated with SPIONs@FA-PAMAM particles 
decreased dramatically as a function of iron concentration. In contrast, there was 
a small decrease in the T2 values of SKOV3 and HeLa cell pellets treated with the 
non-targeted SPIONs@PAMAM particles. In the T2-weighted MR images (the 
color change from red to purple indicates a decrease in MR signal intensity) 
observed in SKOV3 and HeLa cells, targeted SPIONs@FA-PAMAM nanoparticles 
at 80 μg/ml reduced the signal intensity to 45.6% and 28% of the initial value (PBS 
control) in SKOV3 and HeLa cells, respectively; whereas non-targeted 
SPIONs@PAMAM nanoparticles at 80 μg/ml reduced the signal intensity to 87% 
and 71.4% of the initial value in SKOV3 and HeLa cells, respectively. The results 
suggested the targeted nanoparticles SPIONs@FA-PAMAM can specifically 
hamper the MR signal intensity through folate receptor mediated endocytosis. The 
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results are in accordance with the higher cellular internalization of the targeted 
nanoparticles in the fluorescence microscopic studies. 
The anticancer activity of the CDF loaded nanoformulations was examined 
using the in vitro cytotoxicity assay on SKOV3 and Hela cells. The MTT assay 
results showed a high anticancer activity on SKOV3 and HeLa cells with both the 
formulations with relatively low IC50. It should be noted that the targeted formulation 
SPIONs@FA-PAMAM-CDF showed a higher anticancer activity with lower IC50 as 
compared to the non-targeted formulation SPIONs@PAMAM-CDF when tested at 
a concentration range from 0.25 µM to 5 µM. IC50 values of SPIONs@FA-PAMAM-
CDF were found to be 0.78 µM and 0.87 µM in SKOV3 and HeLa, which were 
lower by 2.29 fold and 2.27 fold as compared to the non-targeted 
SPIONs@PAMAM-CDF in SKOV3 and HeLa, respectively. The better anticancer 
activity of the targeted formulation could be attributed to the targeting effect of FA, 
which helped the formulations have a higher degree of cellular internalization via 
folate receptor mediated endocytosis. Fourth generation PAMAM dendrimers are 
known to be cytotoxic due to the highly positive charge of 64 amino groups on the 
periphery. FA conjugation gave the targeted formulation the ability to target folate 
receptors overexpressed on cancer cells, and also helped reduce the positive 
charge of the nanoconstruct. As a result, SPIONs@FA-PAMAM carrier showed a 
relatively safe profile on both SKOV3 and HeLa cells with more than 90% viable 
cells at all tested concentrations. The results proved that SPIONs@FA-PAMAM 
could be promising carriers for anticancer drug delivery (Fig 7a). The folate 
receptor assay was performed to evaluated the fate of the nanoformulations under 
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blocking the folate receptors. An increase in IC50 values of the targeted formulation 
SPIONs@FA-PAMAM-CDF in SKOV3 and HeLa cells after blocking folate 
receptors was observed. In contrast, IC50 values of the non-targeted formulation 
SPIONs@PAMAM-CDF did not show a significant change after the blocking of 
folate receptors. The results suggested that the higher activity of the targeted 
formulation SPIONs@FA-PAMAM-CDF was due to the active targeting ability of 
the folate-decorated nanoformulations. However, it should be noted that the IC50 
value of SPIONs@PAMAM-CDF was still higher than SPIONs@FA-PAMAM-CDF 
in both SKOV3 and HeLa after the blocking the folate receptors (Fig 7b). The 
results suggested that the blocking of folate receptors on SKOV3 and HeLa cells 
could decrease the cellular uptake of the targeted formulation to a certain degree, 
and when the folate receptors are recycled, the folate receptor mediate 
endocytosis pathway was recovered and the targeting ability of SPIONs@FA-
PAMAM was regained. 
As a next step, apoptosis assay and western blot studies were performed 
to further examine the targeting ability of the targeted formulation SPIONs@FA-
PAMAM-CDF in anticancer activity against HeLa cells. It should be noted that free 
CDF showed the highest percentage of apoptotic and necrotic cells. This could be 
explained by the small molecular weight and the highly lipophilic profile of CDF 
which gives CDF a high rate of internalization of passive diffusion. Apoptosis assay 
showed a higher percentage of apoptotic and necrotic cells in HeLa after treatment 
with the targeted formulation SPIONs@FA-PAMAM-CDF as compared to the non-
targeted formulation SPIONs@PAMAM-CDF. A better apoptosis induction ability 
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of the targeted formulation SPIONs@FA-PAMAM-CDF could be explained by a 
higher cellular uptake of the formulation due to the targeting ability of FA to the 
folate receptors overexpressed on HeLa cells [Fig 7c]. The results from apoptosis 
assay were in accordance with higher anticancer activity of the targeted 
formulation with higher cellular uptake in fluorescence microscopic studies and in 
vitro T2 relaxation studies. 
Western blot studies were performed on HeLa cells to determine the 
expression levels of PTEN and NF-κB after treatment with the formulations. CDF 
is known to upregulate PTEN, which is a tumor suppressor gene with a key role in 
stem cell self-renewal [86]. PTEN can dephosphorylate phosphatidylinositol 3,4,5-
triphosphate (PIP3) an antagonize the PI3-K/Akt pathway. It is believed that PTEN 
downregulation is a key factor contributing to the development of chemotherapy 
resistance and recurrence of various human tumors [108]. PTEN is known to 
regulate many cellular processes including growth, adhesion, migration, invasion, 
and apoptosis [11,86]. Nuclear factor kappa B (NF-κB) is known to upregulate anti-
apoptotic genes such as bcl-xL and X-linked inhibitor of apoptosis (XIAP) leading 
to induce cell survival. Activation of NF-κB was observed in many types of cancer 
and was shown to contribute to apoptosis resistance in cancer cells [109]. In case 
of NF-κB expression, control HeLa cells without treatment showed a high 
expression of NF-κB. After treatment with CDF and the formulations, NF-κB levels 
in HeLa were decreased. Higher downregulation of NF-κB in HeLa cells was found 
when cells treated with the targeted formulation SPIONs@FA-PAMAM-CDF 
(decreased by 1.3 folds as compared to control) as compared to the non-targeted 
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formulation SPIONs@PAMAM-CDF (decreased by 1.19 folds as compared to 
control), indicating a better anticancer activity of the targeted formulation. In case 
of PTEN expression, western blot results showed a significantly low expression of 
PTEN in control cells. However, there was an increase in PTEN expression in cells 
treated with CDF and both of the formulations. Noticeably, PTEN level in cells 
treated with the targeted formulation SPIONs@FA-PAMAM-CDF was higher than 
CDF and the non-targeted formulation SPIONs@PAMAM-CDF. As compared to 
control, PTEN expression was upregulated by 3.2 folds in HeLa treated with the 
targeted formulation; whereas, in HeLa treated with free CDF and the non-targeted 
formulation, PTEN expression was increased by 1.58 and 2.14 folds, respectively 
[Fig 8]. The results suggested the ability of the targeted formulation SPIONs@FA-
PAMAM-CDF to upregulate PTEN and downregulate NF-κB, which is known to 
play an important role in tumor suppressor activity and cancer cell death. 
Summary 
In this study, theranostic nanoparticles for cancer imaging and therapy were 
successfully fabricated with SPIONs in the core and FA-PAMAM conjugates on 
the periphery. To our knowledge, this is the first study employing a simple and 
efficient carbodiimide coupling chemistry to fabricate SPIONs decorated PAMAM 
dendrimers for MR imaging and targeted anticancer drug delivery. This fabrication 
method could be used to encapsulate different types of hydrophobic anticancer 
drugs for targeting MRI and therapy in various types of cancers by using 
appropriate targeting molecules for specific recognition of unique biomarkers 
overexpressed on cancer cells. In this study, the fabricated magnetic nanoparticles 
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SPIONs@FA-PAMAM showed great potential to be a promising MR contrast agent 
as well as an anticancer drug delivery system for CDF, a potent anticancer but 
highly lipophilic compound. The targeted nanoparticles SPIONs@FA-PAMAM 
possesses numerous favorable characteristics such as improved aqueous 
solubility of CDF, biological safety and targeting ability to cancer cells due to the 
presence of FA. As compared to SPIONs@PAMAM, SPIONs@FA-PAMAM 
showed a better ability to enhance MR contrast with a faster cellular uptake in in 
vitro T2-weighted images and fluorescence microscopic studies. In addition, 
targeted formulation SPIONs@FA-PAMAM-CDF showed a higher anticancer 
activity, a higher percentage of apoptotic and necrotic cells with the ability to 
upregulate PTEN and downregulate NF-κB which could help overcome anticancer 
drug resistance and the recurrence of cancer after initial treatment. The results 
showed a promising potential of SPIONs@FA-PAMAM-CDF in targeted MRI and 
therapy in cancer, warranting further in vivo investigations underway in our 
laboratory. 
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ABSTRACT 
 
DENDRIMER-COATED IRON OXIDE THERANOSTIC NANOPARTICLES  
FOR CANCER IMAGING AND THERAPY 
by 
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Advisor: Dr. Arun Iyer 
Major: Pharmaceutical Sciences 
Degree: Master of Science 
The bleak prognosis for patients diagnosed with metastatic cancer along 
with the low therapeutic efficacy and the recurrence of cancer in conventional 
chemotherapy are prompting clinical medicine to adopt a new strategy to detect 
cancer in early stage and to deliver the anticancer drugs specifically to tumor site 
to enhance therapeutic efficiency and minimize side effects. The aim of this study 
is to design a theranostic nanocarrier consisting of iron oxide nanoparticles 
(SPIONs) for magnetic resonance imaging (MRI) and Polyamidoamine dendrimers 
conjugated with folic acid (FA-PAMAM) for active targeted delivery of a highly 
potent but extremely lipophilic anticancer compound 3,4-difluorobenzylidene 
diferuloylmethane (CDF). The resulting targeted nanoparticles SPIONs@FA-
PAMAM-CDF showed a significantly enhanced MR contrast as compared to the 
non-targeted nanoparticles. When tested on SKOV3 (ovarian cancer cells) and 
HeLa (cervical cancer cells), the targeted nanoformulations showed a higher 
accumulation in cancer cells with a better anticancer activity, a larger population 
of apoptotic cells and the ability to upregulate tumor suppressor phosphatase and 
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tensin homolog (PTEN) and inhibit nuclear factor kappa B (NF-κB) which further 
confirmed the ability of the folate decorated nanoparticles for targeted MRI and 
anticancer drug delivery. 
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